Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $67.87 billion. The enterprise value is $52.89 billion.
| Market Cap | 67.87B |
| Enterprise Value | 52.89B |
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, before market open.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | Feb 20, 2025 |
Share Statistics
REGN has 107.02 million shares outstanding. The number of shares has increased by 1.23% in one year.
| Current Share Class | 105.21M |
| Shares Outstanding | 107.02M |
| Shares Change (YoY) | +1.23% |
| Shares Change (QoQ) | -2.07% |
| Owned by Insiders (%) | 3.61% |
| Owned by Institutions (%) | 89.18% |
| Float | 103.00M |
Valuation Ratios
The trailing PE ratio is 16.54 and the forward PE ratio is 14.88. REGN's PEG ratio is 2.32.
| PE Ratio | 16.54 |
| Forward PE | 14.88 |
| PS Ratio | 4.82 |
| Forward PS | 4.57 |
| PB Ratio | 2.32 |
| P/TBV Ratio | 2.41 |
| P/FCF Ratio | 18.52 |
| P/OCF Ratio | 15.35 |
| PEG Ratio | 2.32 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.43, with an EV/FCF ratio of 14.43.
| EV / Earnings | 11.99 |
| EV / Sales | 3.72 |
| EV / EBITDA | 11.43 |
| EV / EBIT | 12.76 |
| EV / FCF | 14.43 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.73 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | 0.80 |
| Interest Coverage | 75.09 |
Financial Efficiency
Return on equity (ROE) is 15.95% and return on invested capital (ROIC) is 8.49%.
| Return on Equity (ROE) | 15.95% |
| Return on Assets (ROA) | 7.31% |
| Return on Invested Capital (ROIC) | 8.49% |
| Return on Capital Employed (ROCE) | 12.26% |
| Revenue Per Employee | $940,156 |
| Profits Per Employee | $292,109 |
| Employee Count | 15,106 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.51 |
Taxes
In the past 12 months, REGN has paid $367.30 million in taxes.
| Income Tax | 367.30M |
| Effective Tax Rate | 7.68% |
Stock Price Statistics
The stock price has decreased by -34.45% in the last 52 weeks. The beta is 0.27, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -34.45% |
| 50-Day Moving Average | 688.23 |
| 200-Day Moving Average | 901.25 |
| Relative Strength Index (RSI) | 35.60 |
| Average Volume (20 Days) | 964,233 |
Short Selling Information
The latest short interest is 2.20 million, so 2.06% of the outstanding shares have been sold short.
| Short Interest | 2.20M |
| Short Previous Month | 2.19M |
| Short % of Shares Out | 2.06% |
| Short % of Float | 2.14% |
| Short Ratio (days to cover) | 2.84 |
Income Statement
In the last 12 months, REGN had revenue of $14.20 billion and earned $4.41 billion in profits. Earnings per share was $38.34.
| Revenue | 14.20B |
| Gross Profit | 7.10B |
| Operating Income | 4.15B |
| Pretax Income | n/a |
| Net Income | 4.41B |
| EBITDA | 4.63B |
| EBIT | 4.15B |
| Earnings Per Share (EPS) | $38.34 |
Balance Sheet
The company has $9.01 billion in cash and $2.94 billion in debt, giving a net cash position of $14.97 billion or $139.91 per share.
| Cash & Cash Equivalents | 9.01B |
| Total Debt | 2.94B |
| Net Cash | 14.97B |
| Net Cash Per Share | $139.91 |
| Equity (Book Value) | 29.35B |
| Book Value Per Share | 273.57 |
| Working Capital | 14.72B |
Cash Flow
In the last 12 months, operating cash flow was $4.42 billion and capital expenditures -$755.90 million, giving a free cash flow of $3.66 billion.
| Operating Cash Flow | 4.42B |
| Capital Expenditures | -755.90M |
| Free Cash Flow | 3.66B |
| FCF Per Share | $34.24 |
Margins
Gross margin is 49.99%, with operating and profit margins of 29.19% and 31.07%.
| Gross Margin | 49.99% |
| Operating Margin | 29.19% |
| Pretax Margin | 33.66% |
| Profit Margin | 31.07% |
| EBITDA Margin | 32.59% |
| EBIT Margin | 29.19% |
| FCF Margin | 25.80% |
Dividends & Yields
This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 0.14%.
| Dividend Per Share | $0.88 |
| Dividend Yield | 0.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 2.30% |
| Buyback Yield | -1.23% |
| Shareholder Yield | -1.09% |
| Earnings Yield | 6.50% |
| FCF Yield | 5.40% |
Analyst Forecast
The average price target for REGN is $990.84, which is 56.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $990.84 |
| Price Target Difference | 56.27% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (5Y) | 7.06% |
| EPS Growth Forecast (5Y) | 13.25% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 9.82 and a Piotroski F-Score of 4.
| Altman Z-Score | 9.82 |
| Piotroski F-Score | 4 |